[HTML][HTML] Potent graft-versus-leukemia effect after reduced-intensity allogeneic SCT for intermediate-risk AML with FLT3-ITD or wild-type NPM1 and CEBPA without …
G Labouré, S Dulucq, M Labopin, R Tabrizi… - Biology of Blood and …, 2012 - Elsevier
To investigate the role of reduced-intensity allogeneic (RIC-allo) stem cell transplant (SCT)
as postremission therapy in adult intermediate-risk patients with acute myelogenous …
as postremission therapy in adult intermediate-risk patients with acute myelogenous …
[PDF][PDF] NPM1 and CEBPA without FLT3-ITD
G Labouré, S Dulucq, M Labopin… - Biol Blood Marrow …, 2012 - cyberleninka.org
The role of allogeneic stem cell transplant (allo-SCT) in adults with intermediate-risk acute
myeloid leukemia (IR-AML) in first complete remission (CR1) is controversial and remains a …
myeloid leukemia (IR-AML) in first complete remission (CR1) is controversial and remains a …
[PDF][PDF] NPM1 and CEBPA without FLT3-ITD
G Labouré, S Dulucq, M Labopin… - Biol Blood Marrow …, 2012 - scholar.archive.org
The role of allogeneic stem cell transplant (allo-SCT) in adults with intermediate-risk acute
myeloid leukemia (IR-AML) in first complete remission (CR1) is controversial and remains a …
myeloid leukemia (IR-AML) in first complete remission (CR1) is controversial and remains a …
[PDF][PDF] NPM1 and CEBPA without FLT3-ITD
G Labouré, S Dulucq, M Labopin, R Tabrizi… - Biol Blood Marrow …, 2012 - core.ac.uk
The role of allogeneic stem cell transplant (allo-SCT) in adults with intermediate-risk acute
myeloid leukemia (IR-AML) in first complete remission (CR1) is controversial and remains a …
myeloid leukemia (IR-AML) in first complete remission (CR1) is controversial and remains a …
[HTML][HTML] Potent Graft-versus-Leukemia Effect after Reduced-Intensity Allogeneic SCT for Intermediate-Risk AML with FLT3-ITD or Wild-Type NPM1 and CEBPA without …
G Labouré, S Dulucq, M Labopin, R Tabrizi… - Biology of Blood and …, 2012 - astctjournal.org
To investigate the role of reduced-intensity allogeneic (RIC-allo) stem cell transplant (SCT)
as postremission therapy in adult intermediate-risk patients with acute myelogenous …
as postremission therapy in adult intermediate-risk patients with acute myelogenous …
Potent graft-versus-leukemia effect after reduced-intensity allogeneic SCT for intermediate-risk AML with FLT3-ITD or wild-type NPM1 and CEBPA without FLT3-ITD
G Labouré, S Dulucq, M Labopin… - Biology of blood …, 2012 - pubmed.ncbi.nlm.nih.gov
To investigate the role of reduced-intensity allogeneic (RIC-allo) stem cell transplant (SCT)
as postremission therapy in adult intermediate-risk patients with acute myelogenous …
as postremission therapy in adult intermediate-risk patients with acute myelogenous …
[PDF][PDF] NPM1 and CEBPA without FLT3-ITD
G Labouré, S Dulucq, M Labopin… - Biol Blood Marrow …, 2012 - researchgate.net
The role of allogeneic stem cell transplant (allo-SCT) in adults with intermediate-risk acute
myeloid leukemia (IR-AML) in first complete remission (CR1) is controversial and remains a …
myeloid leukemia (IR-AML) in first complete remission (CR1) is controversial and remains a …
Potent graft-versus-leukemia effect after reduced-intensity allogeneic SCT for intermediate-risk AML with FLT3-ITD or wild-type NPM1 and CEBPA without FLT3-ITD.
G Labouré, S Dulucq, M Labopin, R Tabrizi… - Biology of Blood and …, 2012 - europepmc.org
To investigate the role of reduced-intensity allogeneic (RIC-allo) stem cell transplant (SCT)
as postremission therapy in adult intermediate-risk patients with acute myelogenous …
as postremission therapy in adult intermediate-risk patients with acute myelogenous …
Potent Graft-versus-Leukemia Effect after Reduced-Intensity Allogeneic SCT for Intermediate-Risk AML with FLT3-ITD or Wild-Type NPM1 and CEBPA without FLT3 …
G Labouré, S Dulucq, M Labopin, R Tabrizi… - Biology of Blood and …, 2012 - infona.pl
To investigate the role of reduced-intensity allogeneic (RIC-allo) stem cell transplant (SCT)
as postremission therapy in adult intermediate-risk patients with acute myelogenous …
as postremission therapy in adult intermediate-risk patients with acute myelogenous …
[HTML][HTML] Potent Graft-versus-Leukemia Effect after Reduced-Intensity Allogeneic SCT for Intermediate-Risk AML with FLT3-ITD or Wild-Type NPM1 and CEBPA without …
G Labouré, S Dulucq, M Labopin, R Tabrizi… - Biology of Blood and …, 2012 - tctjournal.org
To investigate the role of reduced-intensity allogeneic (RIC-allo) stem cell transplant (SCT)
as postremission therapy in adult intermediate-risk patients with acute myelogenous …
as postremission therapy in adult intermediate-risk patients with acute myelogenous …